Table 3.
Analysis of the Top 20 Pathways.
| Pathway | nGenes | Fold Enrichment |
|---|---|---|
| Prolactin signaling pathway | 6 | 51.41955 |
| AGE-RAGE signaling pathway in diabetic complications | 8 | 47.99158 |
| Acute myeloid leukemia | 5 | 44.76826 |
| Notch signaling pathway | 4 | 40.67083 |
| VEGF signaling pathway | 4 | 40.67083 |
| Th17 cell differentiation | 7 | 38.88207 |
| Endocrine resistance | 6 | 37.88809 |
| Regulation of lipolysis in adipocytes | 3 | 32.13722 |
| FoxO signaling pathway | 7 | 32.05544 |
| Pancreatic cancer | 4 | 31.57341 |
| CHAZARD RATIOonic myeloid leukemia | 4 | 31.57341 |
| Sphingolipid signaling pathway | 6 | 30.24679 |
| Progesterone-mediated oocyte maturation | 5 | 29.99474 |
| Chagas disease | 5 | 29.69776 |
| C-type lectin receptor signaling pathway | 5 | 28.84109 |
| Osteoclast differentiation | 6 | 28.56642 |
| Colorectal cancer | 4 | 27.90208 |
| Cellular senescence | 7 | 26.91835 |
| Fc epsilon RI signaling pathway | 3 | 26.46594 |
| Hepatitis B | 7 | 26.08238 |